Sepsis - to Reduce Mortality in the Intensive Care UnitPhase 4NCT07655791
Efficacy and Safety of Oral Nicotinamide as an Adjunctive Therapy in Patients With Sepsis
A Phase 4 study testing Nicotinamide 1000 mg in people with Sepsis - to Reduce Mortality in the Intensive Care Unit, run by Ain Shams University at 1 site in Egypt.
Trial summary
Sepsis is a severe, life-threatening condition caused by an abnormal host response to infection, which includes systemic inflammation, oxidative stress, and increasing organ dysfunction. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sepsis - to Reduce Mortality in the Intensive Care Unit
- What is being tested?
- Nicotinamide 1000 mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 28 Mar 2026to 26 Sep 2026
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients older than 18 years of any gender who were admitted to the intensive care unit
- Diagnosed as sepsis patient with the Sequential Organ Failure Assessment (SOFA) Score described as an Increase in SOFA score ≥2 points due to infection.
Who cannot join
- Pregnant or lactating women
- Patients who had already been taking antioxidant supplements before recruiting.
- Patient with contraindications or reported allergies to Nicotinamide.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of the Efficacy and Safety of Oral Nicotinamide as an Adjunctive Therapy in Patients With Sepsis
Sepsis is a severe, life-threatening condition caused by an abnormal host response to infection, which includes systemic inflammation, oxidative stress, and increasing organ dysfunction. It is frequently associated with bacterial, viral, fungal, or parasite infections, as well as non-infectious illnesses like trauma and pancreatitis. It remains a primary cause of mortality in hospitals, with rates nearing 40% in severely ill patients. pathophysiological, excessive cytokine release (e.g., TNFα, IL-6, IL-1β) and reactive oxygen/nitrogen species lead to mitochondrial injury, immunosuppression, and multiple organ failure. Sepsis diagnosis is guided byNEWS2 \& a SOFA score ≥2, hypotension, and elevated lactate, while worsening SOFA scores predict poor outcomes. Standard management focusses on early antibiotic therapy, fluid resuscitation, and vasoactive support. Standard anti-inflammatory methods using steroidal or non-steroidal medicines may show little efficacy to improve the patient's clinical outcomes. Adjunctive antioxidant therapies, including vitamins C and E, NAC, and melatonin, have demonstrated reductions in oxidative stress and organ dysfunction. Nicotinamide (NAM) (vitamin B3), a precursor of NAD+/NADP+ critical for energy metabolism and cellular repair, has emerged as a potential therapeutic candidate due to its ability to attenuate cytokine production, modulate immune responses, and mitigate oxidative damage. Usual dose of NAM (500mg-1500mg per day) is generally safe. A dose of 1000 mg was found to be safe and effective in reducing the circulating inflammatory cytokines showing a good profile as an anti-inflammatory adjunct therapy. Higher than usual NAM dose can increase the likelihood of adverse effects, such as diarrhea, increased liver enzymes (rarely occurring at doses exceeding 3 grams per day), symptoms of thrombocytopenia (including increased bruising and bleeding), and stomach upset.
Since the role of NAM as adjunct therapy in sepsis management is not yet established, further large-scale clinical studies are recommended to establish its efficacy and safety in sepsis management.
The aim of our study is to evaluate the efficacy and safety of the addition of Nicotinamide (1000mg oral tablet) as an adjunct therapy to improve the outcome of septic patients.
Read the detailed description
Sepsis is a life-threatening medical illness caused by the body's response to an infection, resulting in extensive inflammation. This inflammation can cause a series of changes in the body, leading to restricted blood flow to key organs, causing organ failure and eventually death. Sepsis can be caused by bacteria, viruses, fungi, or parasites, or it can develop due to noninfectious intra-abdominal causes, including severe trauma, pneumonia, pancreatitis, and urinary system infection. Despite advances in medical treatments, sepsis remains a major cause of death globally among hospitalized patients because of its complications. According to reports, Hospital mortality rates were 26% for hospital-wide sepsis and 40% for ICU sepsis. Sepsis was more common in the United States among men, non-white individuals, and the elderly (60 years and older) than among women and white persons.
Severe sepsis is characterized by one or more end-organ failures, while septic shock is characterized by hemodynamic instability despite intravascular volume replacement. The overwhelming immune response and the altered balance between pro-inflammatory and anti-inflammatory mediators contribute to the development of sepsis, making it particularly challenging to treat.
Some possible complications of sepsis include Acute/chronic renal injury, Mesenteric ischemia, Acute liver failure, Myocardial dysfunction, and Multiple organ failure. Previous studies showed that sepsis can cause the disturbance of immunological homeostasis, leading to immunosuppression in sepsis.
The SOFA (Sequential Organ Failure Assessment) score is currently advised for diagnosing both sepsis and septic shock. A diagnosis of sepsis is confirmed in the case of a (SOFA) score ≥ 2. The SOFA system is a simple technique that detects organ failure or dysfunction due to sepsis. Daily, the SOFA scoring scale allocates from 1 to 4 points for each of the following six organ systems, according to the level of dysfunction: The respiratory, circulatory, renal, hematological, hepatic, and central nervous systems. Sepsis is presented by a rise of two or more points in the SOFA score. Moreover, the SOFA score could be a method to assess morbidity in intensive care unit (ICU) sepsis patients.
Cytokines are essential for the effective functioning of critical host immune systems because they regulate the body's reactions to infection, immunological responses, inflammation, and trauma. Modifying the cytokine response is an important aspect of therapy for many severe inflammatory disorders. In septic patients, it has been demonstrated that TNFα, IL-6, and IL-1β correspond with the severity of the disease and its outcome.
Oxidative stress (OS) damage plays a role in the pathogenesis of major disorders such as sepsis-induced multiple organ failure (MOF). Studies in animal models and septic shock patients have revealed an imbalance between the formation of reactive oxygen (ROS) and nitrogen (RNS) species and antioxidant defenses. ROS are produced by phagocytic cells, enzymes such as NADPH oxidase, xanthine oxidase, and iNOS, and enhanced inflammatory mediators via NFκB activation. OS-induced mitochondrial damage is part of the pathogenesis of MOF, subsequent sepsis.
To diagnose sepsis patients: SOFA score ≥ 2, mean arterial pressure (MAP) < 65 mmHg, and serum lactate level ≥ 2 mmol/L. Blood should be collected before initiating antibiotics to guide therapy and help determine the source of infection.
Effective sepsis management requires a combination of rapid interventions and supportive care. It involves different pathophysiological aspects, encompassing empirical antimicrobial treatment (which is promptly administered after microbial tests), fluid (crystalloids) replacement (to be established according to fluid tolerance and fluid responsiveness), and vasoactive agents (e.g., norepinephrine). Administering the appropriate medications on time has been linked to higher survival rates. Supportive care and adjuvant therapy, such as the use of corticosteroids, blood purification techniques, and immunomodulatory therapies, are still under investigation.
The inflammatory response in sepsis has played a significant role, and so, Standard therapy includes the use of steroidal and non-steroidal anti-inflammatory medicines, which have resulted in poor outcomes. Currently, antioxidant therapy in septic shock patients has been demonstrated to be effective in lowering Oxidative Stress (OS) indicators. Similarly, it was discovered that adding antioxidant therapy to the standard therapy in septic shock enhances total antioxidant capacity and reduces OS.
Many therapeutic strategies have focused on controlling the inflammatory response and managing oxidative stress, both of which are central to sepsis pathogenesis. Antioxidants and anti-inflammatory medications aim to counteract the overproduction of reactive oxygen species (ROS) and inflammatory cytokines, potentially reducing damage to tissues and organs. However, the complexity of sepsis, with its multifactorial nature and diverse responses among patients, continues to present challenges for developing more effective treatments.
Patients who receive antioxidants such as vitamin C, vitamin E, NAC, or MT in addition to traditional therapy demonstrate lower levels of pro-inflammatory cytokines and enhanced regulatory function in IL-2, IL-12, and IFN. The antioxidant capacity has improved, and indicators of oxidative stress have decreased, indicating that organ damage has reduced as determined by the SOFA score.
Nicotinamide (or nicotinamide) is a form of vitamin B3 that is often confused with its precursor nicotinic acid (or niacin) . Nicotinamide (NAM; niacin), nicotinic acid (niacin), and NAM riboside (NR) are the three vitamins that make up the components of the water-soluble vitamin B3 family. Nicotinamide is a precursor to two essential cofactors in cellular metabolism: Nicotinamide adenine dinucleotide (NAD) and its phosphate form, NADP. Nicotinamide adenine dinucleotide (NAD+) coenzymes are the primary regulators of cellular metabolism. While metabolic stress and age-related diseases can disrupt the NAD+ system, NAD is essential for several biological functions, such as DNA repair, energy synthesis, and cellular stress mechanisms.
Previous research suggests that NAM can effectively reduce cytokine release and inflammatory cell chemotaxis in skin disorders. Research indicates that NAM can reduce the number of inflammatory macrophages in chemically induced skin cancer. NAM has been shown to inhibit the secretion of cytokines and the chemotaxis of inflammatory cells in inflammatory skin diseases. This suggests that NAM might play a role in modulating immune responses, especially in conditions where excessive inflammation leads to tissue damage, like in psoriasis or eczema.
NAM may have therapeutic potential as a modulator of cytokine effects in inflammatory diseases since it significantly inhibits the proinflammatory cytokine response of IL-1β, IL-6, IL-8, and TNFα after endotoxin stimulation of human whole blood.
In general, Nicotinamide has fewer potential negative effects than other niacin supplements. There are expected mild side effects of NAM as (gastrointestinal upset, Headache, dizziness and Fatigue). However, a medication safety trial reported that consuming larger amounts of Nicotinamide than usual can increase the likelihood of adverse effects, such as diarrhea, increased liver enzymes (rarely occurring at doses exceeding 3 grams per day), symptoms of thrombocytopenia (including increased bruising and bleeding), which is a rare side effect. The severity of nicotinamide-induced adverse effects determines how they are managed. Antacids such as calcium carbonate, probiotics, or taking the dose with food can help ease gastrointestinal distress. Headaches can be treated with basic analgesics such as paracetamol or ibuprofen if not contraindicated. Although dizziness normally requires just supportive care, such as appropriate fluids or oral rehydration, it may be needed. Fatigue has no specific pharmacologic treatment, but improving sleep, staying hydrated, and taking a non-excessive B-complex supplement may assist. Diarrhea caused by large doses can be treated with oral rehydration salts and, if necessary, short-term loperamide, as well as lowering the nicotinamide dose.
Nicotinamide riboside (NR) increases NAD+ + levels and may help lower inflammation, even if metabolic stress and age-related disorders dysregulate the NAD+ + system. A previous Study Proves that NR markedly reduced the gene expression of IL-6 and IL-18 in peripheral blood mononuclear cells Moreover, it was found to reduce the incidence of RRT/death and improve the creatinine outcome in individuals with severe COVID-19-related AKI. Larger randomized trials are required to determine a causal link Given the high morbidity and mortality associated with septic patient, incorporating NAM as an adjunct to standard sepsis care could offer a novel therapeutic approach to improving survival and reducing long-term complications.
- Being tested
- Nicotinamide 1000 mg
- Keywords
- Sepsis, IL-6, NF-kB, anti-inflammatory, Nicotinamide, Mortality
- Medical subject headings
- Sepsis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nicotinamide 1000 mgDrug
Also called Nicotinamide 1000 mg (Niacinamide)
Nicotinamide 1000 mg Tablet
| Study group | Role | What they receive |
|---|---|---|
| Control Group | No intervention | 30 Patients will receive the treatment alone according to the hospital management protocol |
| Interventional Group | Active comparator | 30 Patients will receive 1000mg oral Nicotinamide tablets as an adjunct therapy to the treatment provided to the sepsis patients according to the hospital management protocol. Receives: Drug: Nicotinamide 1000 mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
The Change in SOFA Score
The SOFA (Sequential Organ Failure Assessment) score is a crucial ICU tool that quantifies organ dysfunction with score totaling 0-24, the higher score the worser Outcome
Measured: 7 days of receiving treatment.
Secondary outcomes (6)
Change in IL-6 levels in serum
serum IL-6 level change will be calculated by subtracting the IL-6 level in Day 7 minus Baseline IL-6 level
Measured: At the 7th day of follow up
Change in NF-kB in serum
serum NF-kB level change will be calculated by subtracting the IL-6 level in Day 7 minus Baseline IL-6 level
Measured: At 7th day of follow up
Length of ICU stay (days)
Length of ICU stay measured in days from ICU admission until ICU discharge or death, obtained from patient medical records.
Measured: From ICU admission until ICU discharge or death, up to 28 days
28 day Mortality
to determine the mortality rate
Measured: At the 28th day of follow up
Length of hospital stay (days)
Change in length of hospital stay (days) measured from hospital admission to hospital discharge and obtained from patient medical records.
Measured: From hospital admission until discharge, up to 28 days
Assess the septic patients Mortality rate.
Assess effect of Nicotinamide on change of the Mortality rate in septic patient.
Measured: 28 mortality day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jun 2026
- Study start28 Mar 2026
- Primary completion26 Sep 2026
- Study completion26 Sep 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (24)Papers the sponsor has linked to this study.
- Other trials for Sepsis - to Reduce Mortality in the Intensive Care UnitStudies of the same condition, open and under way.
- More trials run by Ain Shams UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Group I: 30 Patients will receive 1000mg oral Nicotinamide tablets as an adjunct therapy to the treatment provided to the sepsis patients according to the hospital management protocol. Group II: 30 Patients will receive the treatment alone according to the hospital management protocol. Both groups will be monitored for sepsis management by the clinical pharmacist.
- Masking
- None (open label)
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Collaborators
- Egyptian Chinese University
- Responsible party
- Principal investigator, Basma Ahmed ABD EL Sattar Amin, Ain Shams University
- Investigators
- Sarah Farid, PhD, Study director, Clinical Pharmacy department Faculty of Pharmacy AIn SHams University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07655791
- Sponsor's protocol ID
- FMASU MS 17 /2026
- Status last verified
- Mar 2026
- First submitted
- 26 Mar 2026
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Raines NH, Ganatra S, Nissaisorakarn P, Pandit A, Morales A, Asnani A, Sadrolashrafi M, Maheshwari R, Patel R, Bang V, Shreyder K, Brar S, Singh A, Dani SS, Knapp S, Poyan Mehr A, Brown RS, Zeidel ML, Bhargava R, Schlondorff J, Steinman TI, Mukamal KJ, Parikh SM. Niacinamide May Be Associated with Improved Outcomes in COVID-19-Related Acute Kidney Injury: An Observational Study. Kidney360. 2020 Nov 20;2(1):33-41. doi: 10.34067/KID.0006452020. eCollection 2021 Jan 28.
PubMed 35368823Hong G, Zheng D, Zhang L, Ni R, Wang G, Fan GC, Lu Z, Peng T. Administration of nicotinamide riboside prevents oxidative stress and organ injury in sepsis. Free Radic Biol Med. 2018 Aug 1;123:125-137. doi: 10.1016/j.freeradbiomed.2018.05.073. Epub 2018 May 24.
PubMed 29803807Dolopikou CF, Kourtzidis IA, Margaritelis NV, Vrabas IS, Koidou I, Kyparos A, Theodorou AA, Paschalis V, Nikolaidis MG. Acute nicotinamide riboside supplementation improves redox homeostasis and exercise performance in old individuals: a double-blind cross-over study. Eur J Nutr. 2020 Mar;59(2):505-515. doi: 10.1007/s00394-019-01919-4. Epub 2019 Feb 6.
PubMed 30725213Zhang Q, Li J, Zhong H, Xu Y. The mechanism of nicotinamide on reducing acute lung injury by inhibiting MAPK and NF-kappaB signal pathway. Mol Med. 2021 Sep 20;27(1):115. doi: 10.1186/s10020-021-00376-2.
PubMed 34544355Camillo L, Zavattaro E, Savoia P. Nicotinamide: A Multifaceted Molecule in Skin Health and Beyond. Medicina (Kaunas). 2025 Feb 1;61(2):254. doi: 10.3390/medicina61020254.
PubMed 40005371Snaidr VA, Damian DL, Halliday GM. Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety. Exp Dermatol. 2019 Feb;28 Suppl 1:15-22. doi: 10.1111/exd.13819.
PubMed 30698874Fontecha-Barriuso M, Lopez-Diaz AM, Carriazo S, Ortiz A, Sanz AB. Nicotinamide and acute kidney injury. Clin Kidney J. 2021 Sep 23;14(12):2453-2462. doi: 10.1093/ckj/sfab173. eCollection 2021 Dec.
PubMed 34950458Huber R, Wong A. Nicotinamide: An Update and Review of Safety & Differences from Niacin. Skin Therapy Lett. 2020 Nov;25(5):7-11.
PubMed 33196157Perez-Torres I, Aisa-Alvarez A, Casarez-Alvarado S, Borrayo G, Marquez-Velasco R, Guarner-Lans V, Manzano-Pech L, Cruz-Soto R, Gonzalez-Marcos O, Fuentevilla-Alvarez G, Gamboa R, Saucedo-Orozco H, Franco-Granillo J, Soto ME. Impact of Treatment with Antioxidants as an Adjuvant to Standard Therapy in Patients with Septic Shock: Analysis of the Correlation between Cytokine Storm and Oxidative Stress and Therapeutic Effects. Int J Mol Sci. 2023 Nov 22;24(23):16610. doi: 10.3390/ijms242316610.
PubMed 38068931Aisa-Alvarez A, Soto ME, Guarner-Lans V, Camarena-Alejo G, Franco-Granillo J, Martinez-Rodriguez EA, Gamboa Avila R, Manzano Pech L, Perez-Torres I. Usefulness of Antioxidants as Adjuvant Therapy for Septic Shock: A Randomized Clinical Trial. Medicina (Kaunas). 2020 Nov 17;56(11):619. doi: 10.3390/medicina56110619.
PubMed 33213070Martinez ML, Plata-Menchaca EP, Ruiz-Rodriguez JC, Ferrer R. An approach to antibiotic treatment in patients with sepsis. J Thorac Dis. 2020 Mar;12(3):1007-1021. doi: 10.21037/jtd.2020.01.47.
PubMed 32274170Ungerstedt JS, Blomback M, Soderstrom T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol. 2003 Jan;131(1):48-52. doi: 10.1046/j.1365-2249.2003.02031.x.
PubMed 12519385Minne L, Abu-Hanna A, de Jonge E. Evaluation of SOFA-based models for predicting mortality in the ICU: A systematic review. Crit Care. 2008;12(6):R161. doi: 10.1186/cc7160. Epub 2008 Dec 17.
PubMed 19091120Rello J, Valenzuela-Sanchez F, Ruiz-Rodriguez M, Moyano S. Sepsis: A Review of Advances in Management. Adv Ther. 2017 Nov;34(11):2393-2411. doi: 10.1007/s12325-017-0622-8. Epub 2017 Oct 11.
PubMed 29022217Marques A, Torre C, Pinto R, Sepodes B, Rocha J. Treatment Advances in Sepsis and Septic Shock: Modulating Pro- and Anti-Inflammatory Mechanisms. J Clin Med. 2023 Apr 15;12(8):2892. doi: 10.3390/jcm12082892.
PubMed 37109229
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Efficacy and Safety of Oral Nicotinamide as an Adjunctive Therapy in Patients With Sepsis
- ClinicalTrials.gov ID
- NCT07655791
- Acronym / sponsor ID
- FMASU MS 17 /2026
- Keywords
- Sepsis, IL-6, NF-kB, anti-inflammatory, Nicotinamide, Mortality
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Collaborators
- Egyptian Chinese University
- Study start
- 28 Mar 2026 (actual)
- Primary completion
- 26 Sep 2026 (actual)
- Study completion
- 26 Sep 2026 (actual)
- First posted
- 18 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sepsis is a severe, life-threatening condition caused by an abnormal host response to infection, which includes systemic inflammation, oxidative stress, and increasing organ dysfunction. It is frequently associated with bacterial, viral, fungal, or parasite infections, as well as non-infectious illnesses like trauma and pancreatitis. It remains a primary cause of mortality in hospitals, with rates nearing 40% in severely ill patients. pathophysiological, excessive cytokine release (e.g., TNFα, IL-6, IL-1β) and reactive oxygen/nitrogen species lead to mitochondrial injury, immunosuppression, and multiple organ failure. Sepsis diagnosis is guided byNEWS2 \& a SOFA score ≥2, hypotension, and elevated lactate, while worsening SOFA scores predict poor outcomes. Standard management focusses on early antibiotic therapy, fluid resuscitation, and vasoactive support. Standard anti-inflammatory methods using steroidal or non-steroidal medicines may show little efficacy to improve the patient's clinical outcomes. Adjunctive antioxidant therapies, including vitamins C and E, NAC, and melatonin, have demonstrated reductions in oxidative stress and organ dysfunction. Nicotinamide (NAM) (vitamin B3), a precursor of NAD+/NADP+ critical for energy metabolism and cellular repair, has emerged as a potential therapeutic candidate due to its ability to attenuate cytokine production, modulate immune responses, and mitigate oxidative damage. Usual dose of NAM (500mg-1500mg per day) is generally safe. A dose of 1000 mg was found to be safe and effective in reducing the circulating inflammatory cytokines showing a good profile as an anti-inflammatory adjunct therapy. Higher than usual NAM dose can increase the likelihood of adverse effects, such as diarrhea, increased liver enzymes (rarely occurring at doses exceeding 3 grams per day), symptoms of thrombocytopenia (including increased bruising and bleeding), and stomach upset.
Since the role of NAM as adjunct therapy in sepsis management is not yet established, further large-scale clinical studies are recommended to establish its efficacy and safety in sepsis management.
The aim of our study is to evaluate the efficacy and safety of the addition of Nicotinamide (1000mg oral tablet) as an adjunct therapy to improve the outcome of septic patients.
Detailed description
Sepsis is a life-threatening medical illness caused by the body's response to an infection, resulting in extensive inflammation. This inflammation can cause a series of changes in the body, leading to restricted blood flow to key organs, causing organ failure and eventually death. Sepsis can be caused by bacteria, viruses, fungi, or parasites, or it can develop due to noninfectious intra-abdominal causes, including severe trauma, pneumonia, pancreatitis, and urinary system infection. Despite advances in medical treatments, sepsis remains a major cause of death globally among hospitalized patients because of its complications. According to reports, Hospital mortality rates were 26% for hospital-wide sepsis and 40% for ICU sepsis. Sepsis was more common in the United States among men, non-white individuals, and the elderly (60 years and older) than among women and white persons.
Severe sepsis is characterized by one or more end-organ failures, while septic shock is characterized by hemodynamic instability despite intravascular volume replacement. The overwhelming immune response and the altered balance between pro-inflammatory and anti-inflammatory mediators contribute to the development of sepsis, making it particularly challenging to treat.
Some possible complications of sepsis include Acute/chronic renal injury, Mesenteric ischemia, Acute liver failure, Myocardial dysfunction, and Multiple organ failure. Previous studies showed that sepsis can cause the disturbance of immunological homeostasis, leading to immunosuppression in sepsis.
The SOFA (Sequential Organ Failure Assessment) score is currently advised for diagnosing both sepsis and septic shock. A diagnosis of sepsis is confirmed in the case of a (SOFA) score ≥ 2. The SOFA system is a simple technique that detects organ failure or dysfunction due to sepsis. Daily, the SOFA scoring scale allocates from 1 to 4 points for each of the following six organ systems, according to the level of dysfunction: The respiratory, circulatory, renal, hematological, hepatic, and central nervous systems. Sepsis is presented by a rise of two or more points in the SOFA score. Moreover, the SOFA score could be a method to assess morbidity in intensive care unit (ICU) sepsis patients.
Cytokines are essential for the effective functioning of critical host immune systems because they regulate the body's reactions to infection, immunological responses, inflammation, and trauma. Modifying the cytokine response is an important aspect of therapy for many severe inflammatory disorders. In septic patients, it has been demonstrated that TNFα, IL-6, and IL-1β correspond with the severity of the disease and its outcome.
Oxidative stress (OS) damage plays a role in the pathogenesis of major disorders such as sepsis-induced multiple organ failure (MOF). Studies in animal models and septic shock patients have revealed an imbalance between the formation of reactive oxygen (ROS) and nitrogen (RNS) species and antioxidant defenses. ROS are produced by phagocytic cells, enzymes such as NADPH oxidase, xanthine oxidase, and iNOS, and enhanced inflammatory mediators via NFκB activation. OS-induced mitochondrial damage is part of the pathogenesis of MOF, subsequent sepsis.
To diagnose sepsis patients: SOFA score ≥ 2, mean arterial pressure (MAP) < 65 mmHg, and serum lactate level ≥ 2 mmol/L. Blood should be collected before initiating antibiotics to guide therapy and help determine the source of infection.
Effective sepsis management requires a combination of rapid interventions and supportive care. It involves different pathophysiological aspects, encompassing empirical antimicrobial treatment (which is promptly administered after microbial tests), fluid (crystalloids) replacement (to be established according to fluid tolerance and fluid responsiveness), and vasoactive agents (e.g., norepinephrine). Administering the appropriate medications on time has been linked to higher survival rates. Supportive care and adjuvant therapy, such as the use of corticosteroids, blood purification techniques, and immunomodulatory therapies, are still under investigation.
The inflammatory response in sepsis has played a significant role, and so, Standard therapy includes the use of steroidal and non-steroidal anti-inflammatory medicines, which have resulted in poor outcomes. Currently, antioxidant therapy in septic shock patients has been demonstrated to be effective in lowering Oxidative Stress (OS) indicators. Similarly, it was discovered that adding antioxidant therapy to the standard therapy in septic shock enhances total antioxidant capacity and reduces OS.
Many therapeutic strategies have focused on controlling the inflammatory response and managing oxidative stress, both of which are central to sepsis pathogenesis. Antioxidants and anti-inflammatory medications aim to counteract the overproduction of reactive oxygen species (ROS) and inflammatory cytokines, potentially reducing damage to tissues and organs. However, the complexity of sepsis, with its multifactorial nature and diverse responses among patients, continues to present challenges for developing more effective treatments.
Patients who receive antioxidants such as vitamin C, vitamin E, NAC, or MT in addition to traditional therapy demonstrate lower levels of pro-inflammatory cytokines and enhanced regulatory function in IL-2, IL-12, and IFN. The antioxidant capacity has improved, and indicators of oxidative stress have decreased, indicating that organ damage has reduced as determined by the SOFA score.
Nicotinamide (or nicotinamide) is a form of vitamin B3 that is often confused with its precursor nicotinic acid (or niacin) . Nicotinamide (NAM; niacin), nicotinic acid (niacin), and NAM riboside (NR) are the three vitamins that make up the components of the water-soluble vitamin B3 family. Nicotinamide is a precursor to two essential cofactors in cellular metabolism: Nicotinamide adenine dinucleotide (NAD) and its phosphate form, NADP. Nicotinamide adenine dinucleotide (NAD+) coenzymes are the primary regulators of cellular metabolism. While metabolic stress and age-related diseases can disrupt the NAD+ system, NAD is essential for several biological functions, such as DNA repair, energy synthesis, and cellular stress mechanisms.
Previous research suggests that NAM can effectively reduce cytokine release and inflammatory cell chemotaxis in skin disorders. Research indicates that NAM can reduce the number of inflammatory macrophages in chemically induced skin cancer. NAM has been shown to inhibit the secretion of cytokines and the chemotaxis of inflammatory cells in inflammatory skin diseases. This suggests that NAM might play a role in modulating immune responses, especially in conditions where excessive inflammation leads to tissue damage, like in psoriasis or eczema.
NAM may have therapeutic potential as a modulator of cytokine effects in inflammatory diseases since it significantly inhibits the proinflammatory cytokine response of IL-1β, IL-6, IL-8, and TNFα after endotoxin stimulation of human whole blood.
In general, Nicotinamide has fewer potential negative effects than other niacin supplements. There are expected mild side effects of NAM as (gastrointestinal upset, Headache, dizziness and Fatigue). However, a medication safety trial reported that consuming larger amounts of Nicotinamide than usual can increase the likelihood of adverse effects, such as diarrhea, increased liver enzymes (rarely occurring at doses exceeding 3 grams per day), symptoms of thrombocytopenia (including increased bruising and bleeding), which is a rare side effect. The severity of nicotinamide-induced adverse effects determines how they are managed. Antacids such as calcium carbonate, probiotics, or taking the dose with food can help ease gastrointestinal distress. Headaches can be treated with basic analgesics such as paracetamol or ibuprofen if not contraindicated. Although dizziness normally requires just supportive care, such as appropriate fluids or oral rehydration, it may be needed. Fatigue has no specific pharmacologic treatment, but improving sleep, staying hydrated, and taking a non-excessive B-complex supplement may assist. Diarrhea caused by large doses can be treated with oral rehydration salts and, if necessary, short-term loperamide, as well as lowering the nicotinamide dose.
Nicotinamide riboside (NR) increases NAD+ + levels and may help lower inflammation, even if metabolic stress and age-related disorders dysregulate the NAD+ + system. A previous Study Proves that NR markedly reduced the gene expression of IL-6 and IL-18 in peripheral blood mononuclear cells Moreover, it was found to reduce the incidence of RRT/death and improve the creatinine outcome in individuals with severe COVID-19-related AKI. Larger randomized trials are required to determine a causal link Given the high morbidity and mortality associated with septic patient, incorporating NAM as an adjunct to standard sepsis care could offer a novel therapeutic approach to improving survival and reducing long-term complications.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Group I: 30 Patients will receive 1000mg oral Nicotinamide tablets as an adjunct therapy to the treatment provided to the sepsis patients according to the hospital management protocol. Group II: 30 Patients will receive the treatment alone according to the hospital management protocol. Both groups will be monitored for sepsis management by the clinical pharmacist.
| Arm | Type | Receives |
|---|---|---|
| Control Group | No intervention | –30 Patients will receive the treatment alone according to the hospital management protocol |
| Interventional Group | Active comparator | Drug: Nicotinamide 1000 mg30 Patients will receive 1000mg oral Nicotinamide tablets as an adjunct therapy to the treatment provided to the sepsis patients according to the hospital management protocol. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Patients older than 18 years of any gender who were admitted to the intensive care unit
- Diagnosed as sepsis patient with the Sequential Organ Failure Assessment (SOFA) Score described as an Increase in SOFA score ≥2 points due to infection.
Key exclusion criteria (3 listed)
- Pregnant or lactating women
- Patients who had already been taking antioxidant supplements before recruiting.
- Patient with contraindications or reported allergies to Nicotinamide.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nicotinamide 1000 mgAlso: Nicotinamide 1000 mg (Niacinamide)Nicotinamide 1000 mg Tablet | Drug | Interventional Group |
Primary outcome
The Change in SOFA Score
Time frame: 7 days of receiving treatment.
The SOFA (Sequential Organ Failure Assessment) score is a crucial ICU tool that quantifies organ dysfunction with score totaling 0-24, the higher score the worser Outcome
6 secondary outcomes
Change in IL-6 levels in serum
Time frame: At the 7th day of follow up
Change in NF-kB in serum
Time frame: At 7th day of follow up
Length of ICU stay (days)
Time frame: From ICU admission until ICU discharge or death, up to 28 days
28 day Mortality
Time frame: At the 28th day of follow up
Length of hospital stay (days)
Time frame: From hospital admission until discharge, up to 28 days
Assess the septic patients Mortality rate.
Time frame: 28 mortality day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
- Background: PubMed 35368823Raines NH, Ganatra S, Nissaisorakarn P, Pandit A, Morales A, Asnani A, Sadrolashrafi M, Maheshwari R, Patel R, Bang V, Shreyder K, Brar S, Singh A, Dani SS, Knapp S, Poyan Mehr A, Brown RS, Zeidel ML, Bhargava R, Schlondorff J, Steinman TI, Mukamal KJ, Parikh SM. Niacinamide May Be Associated with Improved Outcomes in COVID-19-Related Acute Kidney Injury: An Observational Study. Kidney360. 2020 Nov 20;2(1):33-41. doi: 10.34067/KID.0006452020. eCollection 2021 Jan 28.
- Background: PubMed 29803807Hong G, Zheng D, Zhang L, Ni R, Wang G, Fan GC, Lu Z, Peng T. Administration of nicotinamide riboside prevents oxidative stress and organ injury in sepsis. Free Radic Biol Med. 2018 Aug 1;123:125-137. doi: 10.1016/j.freeradbiomed.2018.05.073. Epub 2018 May 24.
- Background: PubMed 30725213Dolopikou CF, Kourtzidis IA, Margaritelis NV, Vrabas IS, Koidou I, Kyparos A, Theodorou AA, Paschalis V, Nikolaidis MG. Acute nicotinamide riboside supplementation improves redox homeostasis and exercise performance in old individuals: a double-blind cross-over study. Eur J Nutr. 2020 Mar;59(2):505-515. doi: 10.1007/s00394-019-01919-4. Epub 2019 Feb 6.
- Background: PubMed 34544355Zhang Q, Li J, Zhong H, Xu Y. The mechanism of nicotinamide on reducing acute lung injury by inhibiting MAPK and NF-kappaB signal pathway. Mol Med. 2021 Sep 20;27(1):115. doi: 10.1186/s10020-021-00376-2.
- Background: PubMed 40005371Camillo L, Zavattaro E, Savoia P. Nicotinamide: A Multifaceted Molecule in Skin Health and Beyond. Medicina (Kaunas). 2025 Feb 1;61(2):254. doi: 10.3390/medicina61020254.
- Background: PubMed 30698874Snaidr VA, Damian DL, Halliday GM. Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety. Exp Dermatol. 2019 Feb;28 Suppl 1:15-22. doi: 10.1111/exd.13819.
- Background: PubMed 34950458Fontecha-Barriuso M, Lopez-Diaz AM, Carriazo S, Ortiz A, Sanz AB. Nicotinamide and acute kidney injury. Clin Kidney J. 2021 Sep 23;14(12):2453-2462. doi: 10.1093/ckj/sfab173. eCollection 2021 Dec.
- Background: PubMed 33196157Huber R, Wong A. Nicotinamide: An Update and Review of Safety & Differences from Niacin. Skin Therapy Lett. 2020 Nov;25(5):7-11.
- Background: PubMed 38068931Perez-Torres I, Aisa-Alvarez A, Casarez-Alvarado S, Borrayo G, Marquez-Velasco R, Guarner-Lans V, Manzano-Pech L, Cruz-Soto R, Gonzalez-Marcos O, Fuentevilla-Alvarez G, Gamboa R, Saucedo-Orozco H, Franco-Granillo J, Soto ME. Impact of Treatment with Antioxidants as an Adjuvant to Standard Therapy in Patients with Septic Shock: Analysis of the Correlation between Cytokine Storm and Oxidative Stress and Therapeutic Effects. Int J Mol Sci. 2023 Nov 22;24(23):16610. doi: 10.3390/ijms242316610.
- Background: PubMed 33213070Aisa-Alvarez A, Soto ME, Guarner-Lans V, Camarena-Alejo G, Franco-Granillo J, Martinez-Rodriguez EA, Gamboa Avila R, Manzano Pech L, Perez-Torres I. Usefulness of Antioxidants as Adjuvant Therapy for Septic Shock: A Randomized Clinical Trial. Medicina (Kaunas). 2020 Nov 17;56(11):619. doi: 10.3390/medicina56110619.
- Background: PubMed 32274170Martinez ML, Plata-Menchaca EP, Ruiz-Rodriguez JC, Ferrer R. An approach to antibiotic treatment in patients with sepsis. J Thorac Dis. 2020 Mar;12(3):1007-1021. doi: 10.21037/jtd.2020.01.47.
- Background: PubMed 12519385Ungerstedt JS, Blomback M, Soderstrom T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol. 2003 Jan;131(1):48-52. doi: 10.1046/j.1365-2249.2003.02031.x.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Sepsis - to Reduce Mortality in the Intensive Care Unit
Recruiting
Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock
Sepsis - to Reduce Mortality in the Intensive Care Unit, Septic Shock
Enrolling by invitationObservational study
Evaluating the Accuracy of Multiple Blood Tests to Diagnose Sepsis in Adult Burn Patients
Sepsis - to Reduce Mortality in the Intensive Care Unit, Burns Involving 20% or More of Body Surface
RecruitingPhase 2
Adjunctive Fludrocortisone in Septic Shock
Sepsis, Septic Shock
RecruitingObservational study
ROTEM in Sepsis Trauma Outcome in Intensive Care
Sepsis - to Reduce Mortality in the Intensive Care Unit, Trauma Coagulopathy
RecruitingPhase 4
Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis
Sepsis - to Reduce Mortality in the Intensive Care Unit, Sepsis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sarah Farid, PhD study director
Clinical Pharmacy department Faculty of Pharmacy AIn SHams University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Nicotinamide 1000 mg in people with Sepsis - to Reduce Mortality in the Intensive Care Unit, run by Ain Shams University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The Change in SOFA Score (time frame: 7 days of receiving treatment.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07655791, which also lists 24 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.